Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
| AstraZeneca PLC | AZD2816 | COVID-19 vaccine (variant) | Phase 2/3 | Data Released | Intramuscular | COVID-19 |
| AstraZeneca PLC | Evusheld (AZD7442) - (PROVENT) | COVID-19 | Phase 3 | Withdrawn | Intramuscular | COVID-19 |
| AstraZeneca PLC | FASENRA (benralizumab) - (MESSINA) | Eosinophilic Esophagitis | Phase 3 | Data Released | Subcutaneous | Gastroenterology |
| AstraZeneca PLC | FASENRA (benralizumab) - (NATRON) | Hyper-eosinophilic syndrome (HES) | Phase 3 | Data Released | Subcutaneous | Immunology |
| AstraZeneca PLC | IMFINZI (durvalumab) - (CALLA) | Cervical cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | FARXIGA (Dapagliflozin) | COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| AstraZeneca PLC | Durvalumab - (NeoCOAST) | Early-stage non-small-cell lung cancer (NSCLC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
